Showing results (261-270 of 635) with videos related to
Sort By:
Pageof 64
European Journal of Heart Failure|May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.Membranes|February 9, 2021
Fabrication and Physicochemical Study of B2SA-Grafted Poly(vinyl Alcohol)-Graphene Hybrid Membranes for Dehydration of Bioethanol by PervaporationPrakash B Kalahal, Akshay S Kulkarni, Ashok M Sajjan, et al.Journal of the American Heart Association|February 13, 2017
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection FractionLauren G Gilstrap, Gregg C Fonarow, Akshay S Desai, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 6, 2021
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HFThor Ueland, Lars Gullestad, Lei Kou, et al.European Journal of Heart Failure|December 12, 2018
The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetesRasmus Rørth, Pardeep S Jhund, Søren L Kristensen, et al.European Journal of Heart Failure|April 9, 2013
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.JACC. Heart Failure|September 13, 2020
Associations Between Depressive Symptoms and HFpEF-Related OutcomesAlvin Chandra, Michael A D Alcala, Brian Claggett, et al.Journal of the American College of Cardiology|March 24, 2017
Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical PracticeAkshay S Desai, Arvind Bhimaraj, Rupinder Bharmi, et al.Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.Pageof 64